• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Apoptosis in Oncology Drug Pipeline Update 2014 Product Image

Apoptosis in Oncology Drug Pipeline Update 2014

  • ID: 1197079
  • July 2014
  • Region: Global
  • Bioseeker

Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis of cancer cells.
There are today 347 companies plus partners developing 431 apoptotic drugs in 1996 developmental projects in cancer. In addition, there are 10 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 216 drugs. Apoptosis In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 324 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 314 out of the 316 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 65 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.


Note: Product cover images may vary from those shown


Our Clients

Our clients' logos